Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Payables (2019 - 2025)

Historic Payables for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $26.3 million.

  • Harmony Biosciences Holdings' Payables rose 15010.44% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 15010.44%. This contributed to the annual value of $13.7 million for FY2024, which is 2248.17% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Payables stood at $26.3 million for Q3 2025, which was up 15010.44% from $28.3 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Payables peaked at $28.3 million during Q2 2025, and registered a low of $1.0 million during Q4 2021.
  • For the 5-year period, Harmony Biosciences Holdings' Payables averaged around $11.1 million, with its median value being $6.9 million (2022).
  • Its Payables has fluctuated over the past 5 years, first tumbled by 6083.72% in 2021, then surged by 36830.43% in 2023.
  • Harmony Biosciences Holdings' Payables (Quarter) stood at $1.0 million in 2021, then soared by 278.22% to $3.8 million in 2022, then skyrocketed by 368.3% to $17.7 million in 2023, then dropped by 22.48% to $13.7 million in 2024, then skyrocketed by 91.65% to $26.3 million in 2025.
  • Its Payables was $26.3 million in Q3 2025, compared to $28.3 million in Q2 2025 and $17.5 million in Q1 2025.